Literature DB >> 30001871

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

María E Rodríguez-Ruiz1, Claire Vanpouille-Box2, Ignacio Melero3, Silvia Chiara Formenti4, Sandra Demaria5.   

Abstract

Radiotherapy has been used for more than a hundred years as a local tumor treatment. The occurrence of systemic antitumor effects manifesting as regression of tumors outside of the irradiated field (abscopal effect) was occasionally observed but deemed too rare and unpredictable to be a therapeutic goal. This has changed with the advent of immunotherapy. Remarkable systemic effects have been observed in patients receiving radiotherapy to control tumors that were progressing during immune checkpoint blockade, stimulating interest in using radiation to overcome primary and acquired cancer resistance to immunotherapy. Here, we review the immunological mechanisms that are responsible for the ability of focal radiation to promote antitumor T cell responses that mediate tumor rejection and, in some cases, result in systemic effects.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA damage; abscopal effect; antitumor immunity; immunotherapy; ionizing radiation; tumor microenvironment

Mesh:

Year:  2018        PMID: 30001871      PMCID: PMC6326574          DOI: 10.1016/j.it.2018.06.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  82 in total

Review 1.  The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax.

Authors:  Aaron A Goodarzi; Penny Jeggo; Markus Lobrich
Journal:  DNA Repair (Amst)       Date:  2010-10-30

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.

Authors:  Stephan Gasser; Sandra Orsulic; Eric J Brown; David H Raulet
Journal:  Nature       Date:  2005-07-03       Impact factor: 49.962

Review 4.  The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics.

Authors:  Jessica Menis; Saskia Litière; Konstantinos Tryfonidis; Vassilis Golfinopoulos
Journal:  Ann Transl Med       Date:  2016-07

5.  Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.

Authors:  Kristian M Koller; Heath B Mackley; Jason Liu; Henry Wagner; Giampaolo Talamo; Todd D Schell; Colette Pameijer; Rogerio I Neves; Bryan Anderson; Kathleen M Kokolus; Carol A Mallon; Joseph J Drabick
Journal:  Cancer Biol Ther       Date:  2016-12-01       Impact factor: 4.742

6.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Authors:  Bin Zhang; Natalie A Bowerman; Joseph K Salama; Hank Schmidt; Michael T Spiotto; Andrea Schietinger; Ping Yu; Yang-Xin Fu; Ralph R Weichselbaum; Donald A Rowley; David M Kranz; Hans Schreiber
Journal:  J Exp Med       Date:  2007-01-08       Impact factor: 14.307

7.  Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN.

Authors:  Nausica Arnoult; Adriana Correia; Jiao Ma; Anna Merlo; Sara Garcia-Gomez; Marija Maric; Marco Tognetti; Christopher W Benner; Simon J Boulton; Alan Saghatelian; Jan Karlseder
Journal:  Nature       Date:  2017-09-20       Impact factor: 49.962

8.  cGAS surveillance of micronuclei links genome instability to innate immunity.

Authors:  Karen J Mackenzie; Paula Carroll; Carol-Anne Martin; Olga Murina; Adeline Fluteau; Daniel J Simpson; Nelly Olova; Hannah Sutcliffe; Jacqueline K Rainger; Andrea Leitch; Ruby T Osborn; Ann P Wheeler; Marcin Nowotny; Nick Gilbert; Tamir Chandra; Martin A M Reijns; Andrew P Jackson
Journal:  Nature       Date:  2017-07-24       Impact factor: 49.962

9.  Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.

Authors:  Diana Rose E Ranoa; Akash D Parekh; Sean P Pitroda; Xiaona Huang; Thomas Darga; Anthony C Wong; Lei Huang; Jorge Andrade; Jonathan P Staley; Takashi Satoh; Shizuo Akira; Ralph R Weichselbaum; Nikolai N Khodarev
Journal:  Oncotarget       Date:  2016-05-03

10.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

View more
  110 in total

1.  ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.

Authors:  Yang Zhao; Ting Zhang; Yanpu Wang; Dehua Lu; Jinhong Du; Xun Feng; Haoyi Zhou; Ning Liu; Hua Zhu; Shangbin Qin; Chenxin Liu; Xianshu Gao; Zhi Yang; Zhaofei Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 2.  The abscopal effect 67 years later: from a side story to center stage.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Br J Radiol       Date:  2020-02-28       Impact factor: 3.039

3.  Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations.

Authors:  Andrew J Johnsrud; Samir V Jenkins; A Jamshidi-Parsian; Charles M Quick; Edvaldo P Galhardo; Ruud P M Dings; Kieng B Vang; Ganesh Narayanasamy; Issam Makhoul; Robert J Griffin
Journal:  Radiat Res       Date:  2020-12-01       Impact factor: 2.841

4.  Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer.

Authors:  Alexander D Sherry; Rie von Eyben; Neil B Newman; Paulina Gutkin; Ingrid Mayer; Kathleen Horst; A Bapsi Chakravarthy; Marjan Rafat
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-12-03       Impact factor: 7.038

5.  Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.

Authors:  Nobuhiko Kanaya; Shinji Kuroda; Yoshihiko Kakiuchi; Kento Kumon; Tomoko Tsumura; Masashi Hashimoto; Toshiaki Morihiro; Tetsushi Kubota; Katsuyuki Aoyama; Satoru Kikuchi; Masahiko Nishizaki; Shunsuke Kagawa; Hiroshi Tazawa; Hiroyuki Mizuguchi; Yasuo Urata; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

6.  A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.

Authors:  Gabriella Macchia; Roberta Lazzari; Nicoletta Colombo; Concetta Laliscia; Giovanni Capelli; Giuseppe Roberto D'Agostino; Francesco Deodato; Ernesto Maranzano; Edy Ippolito; Sara Ronchi; Fabiola Paiar; Marta Scorsetti; Savino Cilla; Rossana Ingargiola; Alessandra Huscher; Anna Maria Cerrotta; Andrei Fodor; Lisa Vicenzi; Donatella Russo; Simona Borghesi; Elisabetta Perrucci; Sandro Pignata; Cynthia Aristei; Alessio Giuseppe Morganti; Giovanni Scambia; Vincenzo Valentini; Barbara Alicja Jereczek-Fossa; Gabriella Ferrandina
Journal:  Oncologist       Date:  2019-10-10

Review 7.  Targeting innate sensing in the tumor microenvironment to improve immunotherapy.

Authors:  Zhida Liu; Chuanhui Han; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2019-12-16       Impact factor: 11.530

Review 8.  Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Authors:  Oliver Kepp; Aurelien Marabelle; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2019-10-08       Impact factor: 66.675

Review 9.  Oncologic Applications of Long Axial Field-of-View PET/Computed Tomography.

Authors:  Lorenzo Nardo; Austin R Pantel
Journal:  PET Clin       Date:  2021-01

10.  Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling.

Authors:  Chuanhui Han; Zhida Liu; Yunjia Zhang; Aijun Shen; Chunbo Dong; Anli Zhang; Casey Moore; Zhenhua Ren; Changzheng Lu; Xuezhi Cao; Chun-Li Zhang; Jian Qiao; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2020-03-30       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.